HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. (2013)

First Author: HPS2-THRIVE Collaborative Group
Attributed to:  CTSU resubmission: Proposal to increase capacity for methodological improvements in clinical trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/eurheartj/eht055

PubMed Identifier: 23444397

Publication URI: http://europepmc.org/abstract/MED/23444397

Type: Journal Article/Review

Volume: 34

Parent Publication: European heart journal

Issue: 17

ISSN: 0195-668X